Astellas Pharma Gmbh

Curegene K.k.

Nec Corporation

Nippon Telegraph and Telephone Corporation

Pioneer Corporation

Takashi Furutani

Nobuaki Shindo

Hiroyuki Mano

Takatoshi Soga

Sadao Kuromitsu

Akio Kamikawa

Minoru Okada

Masahiko Hayakawa

Hiroyuki Kaizawa

Kenichi Kawaguchi

Isao Kinoyama

Masakazu Imamura

Akio Kakefuda

Yutaka Kondoh

Kentaro Enjo

Nobuaki Taniguchi

Yuriko Tanaka

Takenori Kimura

Masaaki Hirano

Tatsuya Niimi

Hiroki Oka

Yoshito Tanaka

Itsuro Shimada

Minoru Yasuda

Toshihiro Yoshioka

Kazushi Watanabe

Kazuhiko Iikubo

Kazuo Kurosawa

Takahiro Matsuya

Tomohiko Yamaguchi

Kenichi Suzumura

Machiko Shinozuka

Xiaoxi Zhang

Katsuya Hayashi

Yasushi Amano

Akira Takeuchi

A summary generation unit includes a processor and a memory storing program instructions that cause the processor to: extract, based on components of text data regarding an Information and Communication Technology (ICT) service, one or more pieces of first feature information from the text data; a extract, based on components of a target belonging to a goal of sustainable development goals (SDGs), one or more pieces of second feature information from the target; determine a degree of similarity between the first feature information and each of the one or more pieces of second feature information; and generate a result of a cluster analysis of a set of the components that correspond to a piece of second feature information having the similarity equal to or more than a threshold among the one or more pieces of second feature information, the result of the cluster analysis being a summary of the goal.

Abstract generation apparatus, abstract generation method and program

An evaluation device includes a first calculation unit configured to calculate feature quantities of respective words, the feature quantities corresponding to text data in which a target of any goal of the SDGs is described and text data in which an outline of one or more first services for which a contribution to the goal that is clear is described, a generation unit configured to generate a sentence feature matrix based on the feature quantities of the respective words, a second calculation unit configured to calculate, when text data in which an outline of a second service is described is input, feature quantities of respective words, and an evaluation unit configured to evaluate a degree of a contribution of the second service to the goal based on the feature quantities of the respective words relevant to the second service and the sentence feature matrix.

Evaluation apparatus and evaluation method

The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.

EML4-ALK fusion gene

As a result of studies on compounds having a selective inhibitory activity against 17&#x3b2;HSD type 5, the present inventors have confirmed that a {1-[(indol-2-yl)carbonyl]piperidyl}alkanol derivative has a potent selective inhibitory activity against 17&#x3b2;HSD type 5. The invention has been completed based on these findings. The compound of the present invention can be used as an agent for treating and/or an agent for preventing diseases associated with 17&#x3b2;HSD type 5, such as benign prostatic hyperplasia and prostate cancer, without accompanying adverse effects due to a decrease in testosterone.

Piperidine derivative

The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive cancer, EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive lung cancer, or EML4-ALK fusion polynucleotide-positive and/or mutant EGFR polynucleotide-positive non-small cell lung cancer, etc.

Di(arylamino)aryl compounds

To provide a novel and excellent method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17&#x3b2;HSD type 5. It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17&#x3b2;HSD type 5 and may become a therapeutic agent and/or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone, and the present invention has thus been completed.

17&#x3b2;HSD type 5 inhibitor

The present invention relates to a novel N-phenyl-(2R,5S)dimethylpiperazine derivatives useful as antiandrogenic agent which exhibits a sufficient prostate gland reducing effect as compared with conventional compounds and are excellent in oral activity. The compound of the present application is useful in preventing or treating prostate cancer, benign prostatic hyperplasia, and the like. The present invention also provides a novel intermediate useful in producing the compound of the present invention.

N-phenyl-(2R,5S)dimethylpiperazine derivative

The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, and a therapeutic agent for cancer.

N-phenyl-(2R,5S) dimethylpiperazine derivative

A plasma display panel includes (a) first and second substrates facing each other, (b) a plurality of first electrodes formed on the first substrate and extending in parallel with one another, (c) a plurality of second electrodes formed on the second substrate and extending in parallel with one another perpendicularly to the first electrodes, and (d) a plurality of display cells arranged at intersections of the first electrodes with the second electrodes, wherein a first selection pulse is input into the first electrodes and a second selection pulse is input selectively into one or more of the second electrodes to thereby control whether light is to be emitted in each of the display cells, and at least one of the display cells has a third electrode formed on the first substrate and being electrically connected to a first electrode other than a first electrode belonging to a display cell to which the third electrode belongs.

Plasma display panel and method of driving the same

A method of driving an ac-discharge type PDP is provided, which expands the permissible range of the voltage applied across the scan and data electrodes at writing discharge and which ensures desired writing discharge generation even if the writing voltage has a comparatively small amplitude. First, (a) a wall-charge adjustment step of storing first wall-charge of a first polarity near the respective scan electrodes and second wall-charge of a second polarity near the respective sustain electrodes is performed, where the second polarity is opposite to the first polarity. The first wall-charge of the first polarity stored near the respective scan electrodes generates an associate electric-field in the cells. The step (a) is performed by common application of at least one of a first wall-charge adjustment voltage pulse to the scan electrodes and a second wall-charge adjustment voltage pulse to the sustain electrodes. Thereafter, (b) a writing discharge generating step of generating writing discharge in the desired cells is performed. The step (b) is performed applying successively a scan voltage pulse to the scan electrodes and applying a data voltage pulse to the data electrodes according to desired image data. The main electric-field generated by the scan and data voltage pulses cooperates with the associate electric-field, thereby generating a desired writing voltage in the cells.

Method of driving ac-discharge plasma display panel

Growing community of inventors

Tokyo, Japan

Takashi Furutani